Premature infants have been known to die from pulmonary failure for many years. In the 1950s this cause of mortality in the neonatal period was treated supportively with temperature regulation, oxygen, and antibiotics. In the early 1960s it was determined that pulmonary failure was caused by lack of a surface active substance in the lung . This substance was named pulmonary surfactant, and the clinical disorder was named respiratory distress syndrome (RDS). The pathologic description of the disorder led to the name ‘‘hyaline membrane disease” . Therapies encompassing more specific measures, such as continuous positive airway pressure, ventilatory support, nutrition, and medications such as sodium bicarbonate, were devised to improve survival in infants with RDS [3,4]. Even with the utilization of these measures, RDS was still the major factor contributing to death in 11,900 infants per year in the years 1969 to 1973. The average contribution of RDS to the neonatal mortality rate—20%— made it the highest single factor associated with death in neonates .
KeywordsContinuous Positive Airway Pressure Respiratory Distress Syndrome Patent Ductus Arteriosus Lamellar Body Surface Active Substance
Unable to display preview. Download preview PDF.
- 1.Avery ME, Mead J: Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 97:517–523, 1959.Google Scholar
- 5.Ferrell PM, Wood RE: Epidemiology of hyaline membrane disease in the United States: Analysis of national mortality statistics. Pediatrics 58:167–176, 1976.Google Scholar
- 6.Liggans GC, Howie RN: A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 50:515–525, 1972.Google Scholar
- 7.Collaborative Group on Antenatal Steroid Therapy: Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. Am J Obstet Gynecol 141:276–286, 1981.Google Scholar
- 11.Notter RH, Finkelstein JN: Pulmonary surfactant: An interdisciplinary approach. J Appl Physiol: Respir Environ Exer Physiol 57(6): 1613–1624, 1984.Google Scholar
- 12.Sanders RL: Lung development: Biological and clinical perspectives. In Ferrell PM (Ed): New York: Academic Press, 1982, pp. 192–210.Google Scholar
- 13.Shapiro DL, Notter RH, Morin FC, et al: Double-blind, randomized trial of calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics 76:594–599, 1985.Google Scholar
- 16.Hagwood S, Schlueter MA, Brown CL, et al: Effects of phospholipids (PL), recombinant human surfactant glycoprotein (SP28–36) and human surfactant proteins (SP5, SP18) on the pulmonary mechanics of premature rabbits. Pediatr Res 21(4):454A, 1987.Google Scholar
- 17.Nogee LM, Rice WR, Whitsett JA: Role of distinct pools of surfactant protein (SAP-35) in regulation of surfactant secretion. Pediatr Res 21(4):461 A, 1987.Google Scholar
- 18.Glasser SW, Korfhagen TR, Weaver LTE: Cloning and predicted structure of hydrophobic surfactant protein SPL (Phe). Pediatr Res 21(4):361 A, 1987.Google Scholar
- 20.Ballard PL, Hawgood S, Wellenstein GA, et al: Surfactant protein of 18,000 dalton (SP 18) in human fetal lung. Pediatr Res 21(4):442A, 1987.Google Scholar
- 29.Fujiwara T: Surfactant replacement in neonatal RDS. In Robertson B, VanGolde LMG, Batenburg JJ (Eds): Pulmonary Surfactant. Amsterdam: Elsevier Science Publishers, 1984, pp. 479–503.Google Scholar
- 34.Dunn MS, Shennan AT, Hoskins EM, et al: Two year follow-up of infants enrolled in a randomized trial of surfactant supplementation. Pediatr Res 21(4):359A, 1987.Google Scholar